Clinical Trials
16 trialsNCT03434678 2025-07-30
Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT00263575 2024-06-18
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT02480114 2021-02-18
Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy
Vanderbilt-Ingram Cancer Center
Phase 3 Completed
NCT00683995 2020-08-28
A Phase III Clinical Study of KW-2246
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00684632 2020-08-28
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00293033 2019-11-18
Study of BEMAâ„¢ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
BioDelivery Sciences International
Phase 3 Completed
NCT00696137 2019-09-24
Long-term Extension Study of BEMAâ„¢ Fentanyl
BioDelivery Sciences International
Phase 3 Completed
NCT00542542 2015-04-13
Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00458510 2013-07-11
Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
Archimedes Development Ltd
Phase 3 Completed
NCT00641667 2013-06-07
An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain
Janssen Pharmaceutical K.K.
Phase 3 Completed
NCT00236145 2013-01-29
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT00279344 2012-05-07
Efficacy and Safety of FITpatch Compared to Standard Opioid Treatment in Cancer Pain (FT-015-IN)
Nycomed
Phase 3 Completed
NCT00362583 2012-05-07
Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)
Nycomed
Phase 3 Completed
NCT00459277 2012-01-25
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed
NCT00589823 2010-01-22
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed